Moreno C, Byrd JC, Hillmen P, et al. Ibrutinib in previously treated chronic lymphocytic leukemia updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 2017, abstract S769.
Rilzabrutinib actief en veilig bij immuuntrombocytopenie
jun 2022 | Benigne hematologie